Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, 15 November, 2012 –Astellas Pharma Inc. (Tokyo: 4503, ”Astellas”) announced today that it received a notice from AstraZeneca not to exercise an exclusive option to acquire the Phase...
Read more about Astellas Announces Acquisition of Own Shares
CAMBRIDGE, Mass. and TOKYO, Japan, October 1, 2012 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO-1 trial (TIvozanib Versus...
Read more about Medivation and Astellas Announce New Data From XTANDI® (enzalutamide) Pivotal Study
CAMBRIDGE, Mass. and TOKYO, Japan, September 28, 2012 -- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that AVEO has submitted a New Drug Application (NDA) to...
Tokyo, Japan, September 26, 2012 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced that it has been selected for the second consecutive year in the Dow Jones Sustainability Asia Pacific...
Tokyo, Japan, September 20, 2012 –The High Energy Accelerator Research Organization (KEK) and Astellas Pharma Inc. (Tokyo:4503,“Astellas”) have today concluded an agreement to begin...
Tokyo, September 6, 2012 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced the donation of three high-standard ambulances to local municipalities in Japan. As part of the company’s...
Read more about Donation of Ambulances on First-Aid Day (September 9)
Tokyo, Japan, August 10, 2012 – Astellas Pharma Inc. (“Astellas”, headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) and AstraZeneca K.K. (“AstraZeneca”, headquarters: Osaka;...
Tokyo, August 8, 2012 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that it submitted an application for market authorization...
Tokyo, August 6, 2012 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that it decided to close Urogenix, Inc. (“Urogenix”, Durham, NC,...
Read more about Astellas to Close Urogenix, North Carolina-based Urology Research Facility
Tokyo, July 30, 2012 – Astellas Pharma Inc. (“Astellas,” Tokyo: 4503) today announced that it will hold its annual “Changing Tomorrow Day” (CT Day), an event in which Astellas Group...
Tokyo, Japan, July 30, 2012 – Tokyo Institute of Technology (“Tokyo-Tech”) and Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced on July 30 that they have signed a joint research...
A newly established international public-private partnership (PPP) between TI Pharma, Merck KGaA (Darmstadt, Germany), Astellas Pharma Inc. and the Swiss Tropical and Public Health Institute...
Read more about Astellas and Drais Partner To Develop Second Astellas Compound through Seldar
Follow us
